Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co), which gained label expansion in January 2023 in the adjuvant setting, have broad applicability in many stages and settings of NSCLC and dominate the market, while biomarker-targeted therapeutics increasingly drive segmentation of the space. The range of drug-addressable disease drivers continues to expand, with the entry of KRAS inhibitors and the 2022 approval of Enhertu, the first targeted therapy for previously treated metastatic HER2-mutant NSCLC. Continued drug development in the biomarker and immune checkpoint inhibitor classes, plus further new market entrants, will further drive competition in this commercially lucrative market.
Questions answered
- How will the recent and expected new market entrants shape the treatment landscapes across the various settings and stages (I-IV) of NSCLC?
- Which therapy options will dominate the commercially lucrative first-line metastatic NSCLC setting?
- What are the most promising pipeline products, and what is their forecast uptake and patient share in NSCLC?
- What are NSCLC’s key market drivers and constraints, and how will the market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for NSCLC?
- What factors are constraining the market for NSCLC?
- Drug-treatable population share and major-market sales share in NSCLC: 2022
- Drug-treatable population share and major-market sales share in NSCLC: 2032
- Major-market sales of drug classes in NSCLC: 2022-2032
- Major-market sales of select drugs in NSCLC: 2022-2032
- Major-market sales share of select drugs in NSCLC by patient population (all histologies): 2022 and 2032
- Segment-specific trends
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for non-small-cell lung cancer
- Current treatments used for non-small-cell lung cancer
- Market events impacting the use of key current therapies in non-small-cell lung cancer
- Immune checkpoint inhibitors
- EGFR-targeting agents
- ALK inhibitors
- BRAF/MEK inhibitors
- ROS1 inhibitors
- MET inhibitors
- RET inhibitors
- KRAS inhibitors
- HER2-targeting agents
- Angiogenesis inhibitors
- Cytotoxic agents
- Medical practice
- Localized stage I/II and resectable and unresectable stage III non-small-cell lung cancer
- First-line metastatic nonsquamous non-small-cell lung cancer
- First-line metastatic squamous non-small-cell lung cancer
- Second- and third-line metastatic nonsquamous non-small-cell lung cancer
- Second- and third-line metastatic squamous non-small-cell lung cancer
- Treatment guidelines
- Patient characteristics influencing drug selection
- Region-specific treatment practices
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for non-small-cell lung cancer
- Estimated market authorization dates of key emerging therapies for the treatment of non-small-cell lung cancer
- Immune checkpoint inhibitors
- EGFR inhibitors
- ALK inhibitors
- ROS1 inhibitors
- MET-targeting agents
- KRAS inhibitors
- HER2 inhibitors
- ATR-, CEACAM5-, HER3-, TROP2-, and integrin beta-6-targeting agents
- Adoptive cell therapies
- Therapeutic vaccines
- Angiogenesis inhibitors
- PARP inhibitors
- Cytokine-targeting agents
- Early-phase pipeline analysis
- Key findings
- Access and Reimbursement Overview
- Methodology
- Appendix
Charlotte Jago, Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Jago is a pharmaceutical industry analyst with more than 18 years’ experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.
Natasha Nahar, M.P.H., Senior Epidemiologist, Epidemiology. Ms. Nahar holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai and a bachelor’s degree in dental surgery from BVDU Dental College and Hospital in Sangli.